



- (51) **International Patent Classification:**
C07K 16/28 (2006.01) **A61K 47/48** (2006.01)
A61P 35/00 (2006.01)
- (21) **International Application Number:**
PCT/IB2015/058801
- (22) **International Filing Date:**
13 November 2015 (13.11.2015)
- (25) **Filing Language:** English
- (26) **Publication Language:** English
- (30) **Priority Data:**
62/079,942 14 November 2014 (14.11.2014) US
- (71) **Applicant (for all designated States except US):** **NOVARTIS AG** [CH/CH]; 35 Lichtstrasse, CH-4056 Basel (CH).
- (72) **Inventors; and**
- (71) **Applicants (for US only):** **ABRAMS, Tinya** [US/US]; c/o Novartis Institutes for Biomedical Research, Inc., 250 Massachusetts Avenue, Cambridge, Massachusetts 02139 (US). **COHEN, Steven** [US/US]; c/o Novartis Institute for Functional Genomics, Inc., dba Genomics Institute of the Novartis Research Foundation, 10675 John Jay Hopkins Drive, San Diego, California 92121 (US). **DAMIANO, Jason** [US/US]; c/o Novartis Institutes for Biomedical Research, Inc., 4560 Horton Street, Emeryville, California 94608 (US). **DÜRR, Clemens** [DE/DE]; c/o Novartis Pharma AG, Postfach, CH-4002 Basel (CH). **HUBER, Thomas** [CH/CH]; c/o Novartis Pharma AG, Postfach, CH-4002 Basel (CH). **MENEZES, Daniel** [PT/US]; c/o Novartis Institutes for Biomedical Research, Inc., 4560 Horton Street, Emeryville, California 94608 (US). **MILLER, Kathy** [US/US]; c/o Novartis Vaccines and Diagnostics, Inc., 4560 Horton Street, Emeryville, Califor-

nia 94608 (US). **RENDAHL, Katherine** [US/US]; c/o Novartis Institutes for Biomedical Research, Inc., 4560 Horton Street, Emeryville, California 94608 (US). **RONDEAU, Jean-michel Rene** [FR/FR]; c/o Novartis Pharma AG, Postfach, CH-4002 Basel (CH).

(74) **Agent:** **NOVARTIS AG**; 35 Lichtstrasse, CH-4056 Basel (CH).

(81) **Designated States (unless otherwise indicated, for every kind of national protection available):** AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) **Designated States (unless otherwise indicated, for every kind of regional protection available):** ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))

Published:

— with international search report (Art. 21(3))

[Continued on next page]

(54) **Title:** ANTIBODY DRUG CONJUGATES




Figure 1

(57) **Abstract:** This application discloses anti-P-cadherin antibodies, antigen binding fragments thereof, and antibody drug conjugates of said antibodies or antigen binding fragments. The invention also relates to methods of treating cancer using the antibodies, antigen binding fragments, and antibody drug conjugates. Also disclosed herein are methods of making the antibodies, antigen binding fragments, and antibody drug conjugates, and methods of using the antibodies and antigen binding fragments as diagnostic reagents.





-
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))* — *with sequence listing part of description (Rule 5.2(a))*